{"id":"https://openalex.org/W7225292425","doi":"https://doi.org/10.1136/jitc-2026-sitc2026.0671","title":"671 Checkpoint inhibitors and targeted therapy combination (triple therapy) in treating metastatic melanoma: a systematic review and meta-analysis","display_name":"671 Checkpoint inhibitors and targeted therapy combination (triple therapy) in treating metastatic melanoma: a systematic review and meta-analysis","alternate_titles":[],"publication_year":2026,"publication_date":"2026-11-01","ids":{"openalex":"https://openalex.org/W7225292425","doi":"https://doi.org/10.1136/jitc-2026-sitc2026.0671"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2026-sitc2026.0671","doi":"https://doi.org/10.1136/jitc-2026-sitc2026.0671","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2026-sitc2026.0671","pdf_url":"https://jitc.bmj.com/content/14/Suppl_2/A760.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular Abstracts","raw_type":"proceedings-article"},"parent_works":[],"lineage":["https://openalex.org/W7225292425"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://jitc.bmj.com/content/14/Suppl_2/A760.full.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5117405409","display_name":"Mohammad A. Zaied","orcid":"https://orcid.org/0009-0000-3742-5684","observed_orcids":["https://orcid.org/0009-0000-3742-5684"]},"institutions":[{"id":"https://openalex.org/I156983542","display_name":"Jordan University of Science and Technology","ror":"https://ror.org/03y8mtb59","country_code":"JO","type":"education","lineage":["https://openalex.org/I156983542"]}],"countries":["JO"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Mohammad A Zaied","raw_affiliation_strings":["Jordan University of Science and Technology, Irbid, Jordan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jordan University of Science and Technology, Irbid, Jordan","institution_ids":["https://openalex.org/I156983542"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160826081","display_name":"Pranjal Kumar Singh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I110166357","display_name":"University of Delhi","ror":"https://ror.org/04gzb2213","country_code":"IN","type":"education","lineage":["https://openalex.org/I110166357"]}],"countries":["IN"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Pranjal Kumar Singh","raw_affiliation_strings":["Kirori Mal College, Delhi University, Delhi, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kirori Mal College, Delhi University, Delhi, India","institution_ids":["https://openalex.org/I110166357"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5124159754","display_name":"Areej Amin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Areej Amin","raw_affiliation_strings":["Rawal Institute of Health Sciences, Islamabad, Pakistan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rawal Institute of Health Sciences, Islamabad, Pakistan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160911379","display_name":"Reenam Mushtaq","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I146840658","display_name":"University of Azad Jammu and Kashmir","ror":"https://ror.org/015566d55","country_code":"PK","type":"education","lineage":["https://openalex.org/I146840658"]}],"countries":["PK"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Reenam Mushtaq","raw_affiliation_strings":["Azad Jammu and Kashmir Medical College, Muzaffarabad, Pakistan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Azad Jammu and Kashmir Medical College, Muzaffarabad, Pakistan","institution_ids":["https://openalex.org/I146840658"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5126159932","display_name":"Moath Naser","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I157392197","display_name":"Hashemite University","ror":"https://ror.org/04a1r5z94","country_code":"JO","type":"education","lineage":["https://openalex.org/I157392197"]}],"countries":["JO"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Moath Naser","raw_affiliation_strings":["Hashemite University, Al-Zarqa, Jordan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hashemite University, Al-Zarqa, Jordan","institution_ids":["https://openalex.org/I157392197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5116555937","display_name":"Arun Kumar Maloth","orcid":"https://orcid.org/0009-0001-0972-4297","observed_orcids":["https://orcid.org/0009-0001-0972-4297"]},"institutions":[{"id":"https://openalex.org/I4405262917","display_name":"Kakatiya Medical College","ror":"https://ror.org/002aj6f72","country_code":"IN","type":"education","lineage":["https://openalex.org/I4405262917"]}],"countries":["IN"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Arun K Maloth","raw_affiliation_strings":["Kakatiya Medical College, Warangal, Telangana, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kakatiya Medical College, Warangal, Telangana, India","institution_ids":["https://openalex.org/I4405262917"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160804099","display_name":"Muhammad Khan Buhadur Ali","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142016965","display_name":"King Edward Medical University","ror":"https://ror.org/02rrbpf42","country_code":"PK","type":"education","lineage":["https://openalex.org/I142016965"]}],"countries":["PK"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Muhammad Khan Buhadur Ali","raw_affiliation_strings":["King Edward Medical University, Lahore, Pakistan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"King Edward Medical University, Lahore, Pakistan","institution_ids":["https://openalex.org/I142016965"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160844746","display_name":"Muhammad Hamza","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405258096","display_name":"Saidu Medical College","ror":"https://ror.org/003fz8y18","country_code":"PK","type":"education","lineage":["https://openalex.org/I4405258096"]}],"countries":["PK"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Muhammad Hamza","raw_affiliation_strings":["Saidu Medical College Swat, Saidu Sharif, Pakistan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Saidu Medical College Swat, Saidu Sharif, Pakistan","institution_ids":["https://openalex.org/I4405258096"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5123323693","display_name":"Mahmoud Marouf","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I156983542","display_name":"Jordan University of Science and Technology","ror":"https://ror.org/03y8mtb59","country_code":"JO","type":"education","lineage":["https://openalex.org/I156983542"]}],"countries":["JO"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Mahmoud Marouf","raw_affiliation_strings":["Jordan University of Science and Technology, Amman, Jordan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jordan University of Science and Technology, Amman, Jordan","institution_ids":["https://openalex.org/I156983542"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"A760","last_page":"A760"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.5547000169754028,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.5547000169754028,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.4187000095844269,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.017500000074505806,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.9909999966621399},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9860000014305115},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.9419999718666077},{"id":"https://openalex.org/keywords/triple-therapy","display_name":"triple therapy","score":0.8730000257492065},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9950000047683716},{"id":"https://openalex.org/keywords/dabrafenib","display_name":"dabrafenib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/trametinib","display_name":"trametinib","score":0.996999979019165},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9290000200271606},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9990000128746033},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.7409999966621399},{"id":"https://openalex.org/keywords/fever","display_name":"fever","score":0.7609999775886536},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7390000224113464},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.4020000100135803},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.6050000190734863},{"id":"https://openalex.org/keywords/pd-1-inhibitors","display_name":"PD-1 inhibitors","score":0.5789999961853027},{"id":"https://openalex.org/keywords/mapk-inhibitors","display_name":"MAPK inhibitors","score":0.6029999852180481},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.6200000047683716}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9068999886512756},{"id":"https://openalex.org/C2778830669","wikidata":"https://www.wikidata.org/wiki/Q3011604","display_name":"Dabrafenib","level":5,"score":0.8050000071525574},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.7235999703407288},{"id":"https://openalex.org/C2778472372","wikidata":"https://www.wikidata.org/wiki/Q7833138","display_name":"Trametinib","level":4,"score":0.7197999954223633},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.7085000276565552},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.6489999890327454},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.638700008392334},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.4553000032901764},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.41130000352859497},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.4090000092983246},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.3718999922275543},{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.3675999939441681},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.36320000886917114},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.34279999136924744},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.33059999346733093},{"id":"https://openalex.org/C156957248","wikidata":"https://www.wikidata.org/wiki/Q1862216","display_name":"Odds ratio","level":2,"score":0.31790000200271606},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.3084999918937683},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.30070000886917114},{"id":"https://openalex.org/C500440147","wikidata":"https://www.wikidata.org/wiki/Q701216","display_name":"Pharmacotherapy","level":2,"score":0.2992999851703644},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.28940001130104065},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.289000004529953},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.28679999709129333},{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.2849000096321106},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.27709999680519104},{"id":"https://openalex.org/C2776283816","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Survival rate","level":2,"score":0.27639999985694885}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1136/jitc-2026-sitc2026.0671","doi":"https://doi.org/10.1136/jitc-2026-sitc2026.0671","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2026-sitc2026.0671","pdf_url":"https://jitc.bmj.com/content/14/Suppl_2/A760.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular Abstracts","raw_type":"proceedings-article"},{"id":"pmh:oai:doaj.org/article:64ab96f5501144ceb740b4940d45fe88","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/64ab96f5501144ceb740b4940d45fe88","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal for ImmunoTherapy of Cancer, Vol 14, Iss Suppl 2 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2026-sitc2026.0671","doi":"https://doi.org/10.1136/jitc-2026-sitc2026.0671","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2026-sitc2026.0671","pdf_url":"https://jitc.bmj.com/content/14/Suppl_2/A760.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular Abstracts","raw_type":"proceedings-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7225292425.pdf","grobid_xml":"https://content.openalex.org/works/W7225292425.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4225872326","https://openalex.org/W4392388410","https://openalex.org/W4393071584","https://openalex.org/W4404817765","https://openalex.org/W3168608502","https://openalex.org/W4281627712","https://openalex.org/W4226210933","https://openalex.org/W4379280610","https://openalex.org/W4291130566","https://openalex.org/W3036170650"],"abstract_inverted_index":{"Background":[0],"Immune":[1],"checkpoint":[2],"inhibitors":[3],"(ICIs)":[4],"have":[5],"demonstrated":[6],"durable":[7],"survival":[8,323,331],"benefits;":[9],"targeted":[10,35,87,94],"therapy":[11,31,36,95,128,229,272,275,283],"provides":[12],"rapid":[13],"disease":[14],"control":[15],"in":[16,54,98,124,136,174,195,227,252,269,284],"patients":[17,123,253,285],"with":[18,34,40,100,119,140,155,163,200,217,243,266,286,292],"Metastatic":[19,56,101],"melanoma.":[20],"However,":[21],"there":[22],"are":[23],"high":[24],"resistance":[25],"rates":[26],"when":[27],"used":[28,105],"alone.":[29],"Triple":[30,274],"combining":[32],"ICIs":[33],"has":[37],"emerged,":[38],"but":[39,289],"limited":[41],"evidence.":[42],"We":[43],"aim":[44],"to":[45,72,106,222,248,281],"investigate":[46],"the":[47,255,260,270],"effectiveness":[48],"and":[49,67,80,89,96,121,126,151,167,183,278,298,306,317],"safety":[50],"of":[51,69,85,144,157,204,210],"triple":[52,83,125,228,256,271],"approach":[53],"treating":[55],"Melanoma.Methods":[57],"A":[58],"thorough":[59],"literature":[60],"search":[61],"was":[62,104,193,259],"conducted":[63],"across":[64],"PubMed,":[65],"Scopus":[66],"Web":[68],"Science":[70],"up":[71],"20/Feb/2025.":[73],"Eligible":[74],"studies":[75,115],"included":[76],"RCTs,":[77],"non-randomized":[78],"trials,":[79],"cohorts":[81],"comparing":[82],"consisting":[84],"two":[86],"therapies":[88],"one":[90],"ICI":[91],"versus":[92],"dual":[93,127,282],"placebo":[97],"adults":[99],"Melanoma.":[102],"R":[103],"conduct":[107],"statistical":[108],"analysis.":[109],"PROSPERO":[110],"registration":[111],"number:":[112],"CRD420250655934Results":[113],"10":[114],"including":[116],"8":[117],"RCTs":[118],"1465":[120],"1475":[122],"receptively":[129],"were":[130,134],"included.":[131],"Significant":[132],"difference":[133,192],"observed":[135,194],"Progression-Free":[137],"Survival":[138,153],"(PFS)":[139],"summary":[141],"HR":[142],"(SHR)":[143],"0.69":[145],"(95%CI,":[146,159],"[0.57\u20130.84])":[147],"(":[148],"figure":[149],"1)":[150],"Overall":[152],"(OS)":[154],"SHR":[156],"0.79":[158,180],"[0.67\u20130.93])":[160],"(figure":[161],"2),":[162],"being":[164],"Pembrolizumab,":[165,304],"Dabrafenib":[166,305],"Trametinib":[168],"regimen":[169],"showing":[170],"more":[171,311],"promising":[172],"effect":[173,316],"both":[175],"PFS":[176,277],"(SHR:":[177,185],"0.51":[178],"vs.":[179,181,187],"0.82)":[182],"OS":[184,279],"0.62":[186],"0.84).":[188],"While":[189],"no":[190],"significant":[191,215,238],"Objective":[196],"Response":[197],"Rate":[198],"(ORR)":[199],"an":[201],"Odds":[202],"Ratio":[203],"1.06":[205],"(95%":[206,219,245],"CI":[207],"[0.87\u20131.29]).":[208],"Discontinuation":[209],"all":[211],"drugs":[212],"didn\u2019t":[213],"reach":[214],"level":[216],"0.7%":[218],"CI:":[220,246],"-2.7%":[221],"3.9%)":[223],"higher":[224,250,299],"cessation":[225],"rate":[226],"group,":[230],"while":[231],"discontinuation":[232,251,295],"any":[233],"drug":[234,294],"revealed":[235],"a":[236],"highly":[237],"result":[239],"(p":[240],"<":[241],"0.00001),":[242],"12.8%":[244],"8.1%":[247],"17.5%)":[249],"receiving":[254],"therapy.":[257],"Pyrexia":[258],"most":[261],"frequently":[262],"reported":[263],"adverse":[264,318],"event":[265],"mostly":[267],"happen":[268],"group.Conclusions":[273],"improves":[276],"compared":[280],"advanced":[287],"melanoma":[288],"is":[290],"associated":[291],"increased":[293],"rates,":[296],"toxicities":[297],"cost.":[300],"Further":[301],"regimens,":[302],"especially":[303],"Trametinib,":[307],"should":[308],"be":[309],"navigated":[310],"extensively":[312],"for":[313],"long-term":[314],"treatment":[315],"events.Abstract":[319],"671":[320,328],"Figure":[321,329],"1Progression-free":[322],"hazard":[324,332],"ratio":[325,333],"forest":[326,334],"plotAbstract":[327],"2Overall":[330],"plot":[335]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W7225292425","counts_by_year":[],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2026-11-06T00:00:00"}
